Home/Pipeline/IONIS-MAPTRx (BIIB080)

IONIS-MAPTRx (BIIB080)

Alzheimer's Disease

Phase 2Active (Partnered: Biogen)

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active (Partnered: Biogen)

Company

Ionis Pharmaceuticals

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a commercial-stage biotech leader with a mission to discover and deliver life-changing RNA-targeted medicines. The company has achieved multiple industry firsts, including the first approved antisense drug, and has successfully transitioned from a research-focused entity to a fully integrated organization with its own commercial capabilities. Its strategy centers on independently launching medicines in neurology and cardiology while selectively partnering in other areas, backed by a deep, late-stage pipeline and a sustainable technology platform.

View full company profile

Therapeutic Areas

Neurology Cardiometabolic Rare Genetic Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active